MedTrace Logo

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

NCT04735042 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-07-18

No results posted yet for this study

Summary

In this observational study, 60 subjects with type 2 diabetes (T2D) and eligible, as per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive a SGLT-2 inhibitor or a fixed dose combination of SGLT-2 inhibitor with a DPP4-inihibitor for 12 weeks. Measures will be performed at baseline and after 12 weeks of treatment, as per good clinical practice.

Conditions

Interventions

DRUG

Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill

association between SGLT2-inhibitor and DPP4-inhibitor

DRUG

Empagliflozin or Dapagliflozin Pill

SGLT2-inhibitor: diabetic oral drug with diuretic properties.

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Anna Solini, MD, PhD · University of Pisa

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2021-10-07
Completion
2022-04-07

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735042 on ClinicalTrials.gov